Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
Nuvalent stockholders will receive $124 per share and the aggregate equity value of the transaction is approximately $10.6 billion. Nuvalent insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Nuvalent by imposing a significant penalty if Nuvalent accepts a competing bid. We are investigating the conduct of the Nuvalent board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action